Group 1 - The board of directors of Jiangsu Lanfeng Biological Chemical Co., Ltd. held its 26th meeting on September 3, 2025, via communication methods, with all 8 directors present [1][2] - The board approved the signing of a settlement and debt waiver agreement with Jiangsu Suhua Group Co., Ltd., which is expected to alleviate the company's debt pressure and optimize its asset-liability structure [1] - The agreement does not constitute a related party transaction and does not harm the interests of minority shareholders [1]

Group 1 - The company announced that it will hold the 26th meeting of the 7th Board of Directors on September 3, 2025 [1] - The company approved the proposal regarding the signing of a settlement and debt waiver agreement [1] - The settlement and debt waiver agreement was reached with the former controlling shareholder, Jiangsu Suhua Group Co., Ltd., concerning investor litigation claims and debt waiver [1]

（文章来源：证券日报） 证券日报网讯 9月3日晚间，蓝丰生化发布公告称，公司第七届董事会第二十六次会议审议通过了《关 于公司签署和解及债务豁免协议的议案》。 ...

Core Viewpoint - The company has reached a settlement agreement with its controlling shareholder, Jiangsu Suhua Group Co., Ltd., regarding investor litigation claims and debt waiver, which will alleviate the company's debt pressure and optimize its asset-liability structure [1] Summary by Relevant Sections Settlement Agreement - The company convened its 26th meeting of the 7th Board of Directors on September 3, 2025, to approve the signing of a settlement and debt waiver agreement [1] - The total amount involved in the settlement and debt waiver agreement is 23.1572 million yuan [1] Financial Impact - The signing of the agreement is expected to reduce the company's debt burden and improve its financial structure [1] - The company will adjust the liabilities that have been accrued in accordance with relevant provisions of the Enterprise Accounting Standards, with specific amounts to be determined based on audit results [1]

Core Viewpoint - The company has reached a settlement agreement with its controlling shareholder, Jiangsu Suhua Group Co., Ltd., regarding investor litigation claims and debt waiver, which will alleviate the company's debt pressure and optimize its capital structure [1] Summary by Relevant Sections - **Settlement Agreement**: The company signed a "Settlement and Debt Waiver Agreement" with Jiangsu Suhua Group, involving a total compensation and debt waiver amount of 23.1572 million yuan [1] - **Debt Pressure Relief**: The agreement is expected to reduce the company's debt burden and improve its asset-liability structure [1] - **Accounting Adjustments**: The company will adjust the relevant liabilities in accordance with the "Enterprise Accounting Standards," with specific amounts to be determined based on audit results [1]

证券代码：002513 证券简称：蓝丰生化 公告编号：2025-043 江苏蓝丰生物化工股份有限公司 关于签署《和解及债务豁免协议》的公告 2、根据法院已生效判决及相关其他文书显示，上述投资者诉讼事项公司需 赔偿投资者损失本金人民币22,766,475.6元及逾期利息、诉讼费、执行费等。为 了维护公司及全体股东的合法权益，公司就前述事项已向时任董事长、总经理及 1 控股股东苏化集团发出《律师函》，要求其对投资者诉讼案件给公司造成的损失 承担相应赔偿责任。 3、截至2025年07月31日，公司尚欠苏化集团借款本息人民币83,600,036.66 元（其中本金59,200,719.70元，利息24,399,316.96元）。 近日，为了尽快落实和推进本次追偿事项，公司就上述投资者诉讼索赔案件 及相应债务豁免事项与时任控股股东苏化集团达成和解并签署了《和解及债务豁 免协议》。 本公司及董事会全体成员保证公告内容真实、准确和完整，不存在虚假记 载、误导性陈述或者重大遗漏。 江苏蓝丰生物化工股份有限公司（以下简称"公司"或"蓝丰生化"）于 2025年9月3日召开第七届董事会第二十六次会议，审议通过了《关于公司签署和 解 ...

证券代码：002513 证券简称：蓝丰生化 公告编号：2025-044 表决结果：8 票同意，0 票反对，0 票弃权。 具体详见 2025 年 9 月 4 日刊登在公司指定信息披露网站巨潮资讯网 （www.cninfo.com.cn）及《上海证券报》、《证券时报》、《中国证券报》上 的相关公告。 三、备查文件 江苏蓝丰生物化工股份有限公司 第七届董事会第二十六次会议决议公告 本公司及董事会全体成员保证公告内容真实、准确和完整，不存在虚假记 载、误导性陈述或者重大遗漏。 一、董事会会议召开情况 江苏蓝丰生物化工股份有限公司（以下简称"公司"）第七届董事会第二十 六次会议于 2025 年 9 月 3 日以通讯方式召开。本次会议已于 2025 年 9 月 2 日以 微信、电子邮件的方式通知全体董事，经第七届董事会全体董事同意豁免会议通 知时间要求。本次会议由公司董事长郑旭先生主持，应出席董事 8 人，实际出席 董事 8 人，公司高级管理人员列席会议。本次会议的召集、召开及表决程序符合 《公司法》和《公司章程》的规定，合法有效。 二、董事会会议审议情况 （一）审议通过《关于公司签署和解及债务豁免协议的议案》 经审核， ...

Group 1 - The company has announced the lifting of restrictions on 1,339,746 shares, accounting for 0.357% of the total share capital [1] - Following the completion of a non-public share issuance, the company's total share capital increased from 340,086,278 shares to 373,936,278 shares, and subsequently to 375,280,278 shares after various stock incentive plans and repurchases [2] - The shareholders applying for the lifting of restrictions, Ren Wenbin and Chen Jing, have committed to not transferring their shares for specified periods based on the performance compensation agreements [3][4] Group 2 - The performance compensation agreement stipulates that if the audited net profits of Ark Pharmaceutical for 2015, 2016, and 2017 fall below certain thresholds, the shareholders must compensate the company [5] - The company has initiated legal proceedings against the shareholders for failing to fulfill their performance compensation obligations, resulting in a court ruling requiring them to pay a total of 403.1 million yuan in compensation [6] - The lifting of share restrictions does not involve any non-operating fund occupation or violations of guarantees that could harm the company's interests [6] Group 3 - The financial advisor has confirmed that the shareholders have strictly adhered to their commitments regarding the lifting of share restrictions, and the process complies with relevant laws and regulations [7]

Core Viewpoint - The article discusses the lifting of restrictions on the shares of Jiangsu Lanfeng Bio-chemical Co., Ltd. following a major asset restructuring, detailing the compliance of shareholders with their commitments and the financial implications of this event [1][7]. Summary by Sections 1. Basic Situation of Restricted Shares - Jiangsu Lanfeng Bio-chemical Co., Ltd. completed a major asset restructuring by acquiring 100% equity of Shaanxi Ark Pharmaceutical Co., Ltd. through a combination of issuing shares and cash payments, with the new shares being registered as restricted shares [1]. 2. Shareholders' Commitments and Compliance - The shareholders applying for the lifting of restrictions, Ren Wenbin and Chen Jing, made commitments regarding the transfer of shares based on the duration of their asset ownership, with specific percentages of shares allowed for transfer at different time intervals [2][3]. - Both shareholders adhered to their commitments during the lock-up period and have not transferred their restricted shares [3]. 3. Performance Compensation Agreement - The performance compensation agreement stipulated that if Ark Pharmaceutical's net profit fell below certain thresholds for the years 2015, 2016, and 2017, the shareholders would compensate Jiangsu Lanfeng Bio-chemical in cash or shares [3]. - The shareholders fulfilled their compensation obligations for the years 2015 and 2016, but not for 2017, leading to a total compensation amount of 60.53 million yuan [3]. 4. Legal Proceedings and Compensation Payment - Jiangsu Lanfeng Bio-chemical filed a lawsuit against the shareholders for overdue performance compensation, resulting in a court ruling that required Ren Wenbin to pay 2.9561 million yuan and Chen Jing to pay 1.0749 million yuan, both with penalties [4]. - The company has received all compensation payments from the shareholders, fulfilling their obligations [4]. 5. Details of Restricted Shares Lifting - The lifting of restrictions on the shares will allow 1,339,746 shares to be listed for trading, which represents 0.357% of the company's total shares [4][6]. - The shares will become tradable on September 5, 2025 [4]. 6. Financial Advisor's Opinion - The independent financial advisor confirmed that the shareholders complied with their commitments and that the lifting of restrictions aligns with relevant laws and regulations, ensuring accurate and complete disclosure of information by Jiangsu Lanfeng Bio-chemical [7].

江苏蓝丰生物化工股份有限公司 关于非公开发行股份上市流通的提示性公告 本公司及董事会全体成员保证公告内容真实、准确和完整，不存在虚假记 载、误导性陈述或者重大遗漏。 特别提示： 1、本次解除限售股份为江苏蓝丰生物化工股份有限公司（以下简称"公司"） 2015年度并购陕西方舟制药有限公司（以下简称"方舟制药"）非公开发行A股 股票，本次解除限售股份的数量为1,339,746股，占公司总股本的0.357%； 2、本次解除限售股份上市流通日为2025年9月5日。 证券代码：002513 证券简称：蓝丰生化 公告编号：2025-042 一、公司非公开发行股份概况及股本变化情况 2015年11月20日，中国证券监督管理委员会（以下简称"中国证监会"）下 发《关于核准江苏蓝丰生物化工股份有限公司向王宇等发行股份购买资产并募集 配套资金的批复》（证监许可[2015]2689号），公司通过发行股份及支付现金相 结合的方式向陕西方舟制药有限公司全体股东购买其持有的方舟制药100.00%股 权。公司完成上述非公开发行股份购买资产并募集配套资金相应股份登记手续， 取得中国证券登记结算有限责任公司深圳分公司出具的《股份登记申请受理确 ...